Article
Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation.
Clinical laboratory - 1 Jun 2018
Zeng Yunxin, Zhang Jingwen, Li Xiaoqing, Zhang Ling, Liu Jiajun
Abstract excerpt
BACKGROUND: T315I mutation is the most common BCR-ABL mutation and confers resistance to all the first and second generation BCR-ABL tyrosine kinases, including nilotinib and dasatinib. We report a high risk chronic myelogenous leukemia (CML) patient harboring the T315I mutation treated by Interferon-α (INF-α) solo and subsequently combined with dasatinib. METHODS: Hematological investigation, bone marrow...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.